Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Marijke Timmers(Antwerp University Hospital), Sébastien Anguille(Antwerp University Hospital), Feifei Luo(Jiangxi University of Traditional Chinese Medicine), Yiwei Chu(Fudan University), Heleen H. Van Acker(University of Antwerp), Yuedi Wang(Fudan University), Viggo Van Tendeloo(University of Antwerp), Diana Campillo-Davó(University of Antwerp), Gils Roex(University of Antwerp), Zwi Berneman(University of Antwerp)
Frontiers in Immunology
July 16, 2019
10.3389/fimmu.2019.01613
Cited by 90

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
|Blood|2001|458
SIRT5 Desuccinylates and Activates Pyruvate Kinase M2 to Block Macrophage IL-1β Production and to Prevent DSS-Induced Colitis in Mice
|Cell Reports|2017|340
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|264
CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus.
|Proceedings of the National Academy of Sciences|1994|221